Exacerbation of well‐controlled bullous pemphigoid by the administration of a dipeptidyl peptidase‐4 inhibitor

Nishiyama, Chiaki; Tateishi, Chiharu; Hashimoto, Takashi; Nishida, Mana; Imanishi, Akiko; Shiratori, Takahiro; Maekawa, Naoki; Tsuruta, Daisuke; Fukai, Kazuyoshi

doi:10.1111/ced.13962

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…77 Patients with DPP4i-induced BP have autoantibodies targeting the midportion of collagen XVII, the C terminus and LABD97, the processed extracellular domain of collagen XVII. 66,68,[78][79][80][81][82][83][84][85] Yet, amongst DPP4i-induced BP cases without reactivity against NC16A, epitope spreading can result in the subsequent seroconversion to anti-NC16A antibodies, especially amongst the elderly or with prolonged use of DPP4i. 82,[86][87][88] For instance, patients with anti-full-length collagen XVII IgG-positive reactivity are significantly older compared to patients with negative reactivity (median age in years 74 vs. 69).…”

Section: Bullous Pemphi G Oid and Mucous Memb R Ane Pemphigoidmentioning

confidence: 99%

The role of Dipeptidyl Peptidase‐4 in cutaneous disease

Patel

Jones

Kridin

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 (DPP4) is a multifunctional, type II transmembrane glycoprotein expressed on the cell surface of many tissues. 1,2 Its soluble form (aa 49-766) is also found in various bodily fluids (Figure 1). 3 CD26 is a cell surface marker with DPP4 enzymatic activity in its extracellular domain. For uniformity, we will use the term CD26 + or CD26 − to indicate the presence or absence of DPP4 as a cell surface marker but use DPP4 in reference to the enzyme and gene/protein expression. Dipeptidyl peptidase-4 is a serine exopeptidase, which cleaves X-proline or X-alanine dipeptide residues in the penultimate position from the NH 2-terminus of polypeptide substrates, including chemokines, neuropeptides and hormones. 4-6 The cysteine-rich domain of DPP4 interacts with the proteins of the extracellular matrix whilst the glycosylation-rich domain interacts with adenosine deaminase and caveolin-1 amongst others. 5,7,8 DPP4 inhibitors (DPP4i) are best known for their role in the treatment of diabetes mellitus due to their ability to deactivate incretins, such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. 9 The rise of DPP4 inhibitors, however, is also accompanied by undesired cardiovascular and dermatologic manifestations. 10-12 More recently, the role of DPP4 and its inhibition in various dermatoses including bullous pemphigoid, psoriasis and mycosis fungoides have been described. In this review, we sought to summarize the role of DPP4 expression, regulation, and inhibition in cutaneous diseases.

show abstract

Section: Bullous Pemphi G Oid and Mucous Memb R Ane Pemphigoidmentioning

confidence: 99%

The role of Dipeptidyl Peptidase‐4 in cutaneous disease

Patel

Jones

Kridin

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Moreover, a few meta-analyses[ 63 , 64 ] tried to sum-up the available data. DPP-4i use in diabetes is associated with both de novo development of BP as well as exacerbation of the already existing BP[ 65 ]. It is also important to note that studies have reported increasing diabetes prevalence in BP patients[ 66 ], so one should be cautious while prescribing DPP-4i in these patients.…”

Section: Dpp-4i Use and Risk Of Bpmentioning

confidence: 99%

Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence

Roy¹,

Sahoo²,

Narayanan³

et al. 2021

WJD

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 inhibitors (DPP-4i) have an important place in the management of type 2 diabetes. The DPP-4 enzyme is ubiquitously distributed throughout the human body and has multiple substrates through which it regulates several important physiological functions. DPP-4 regulates several immune functions, including T-cell activation, macrophage function, and secretion of cytokines. Studies have reported an increase in autoimmune diseases like bullous pemphigoid, inflammatory bowel disease, and arthritis with DPP-4i use. The relationship of DPP-4i and autoimmune diseases is a complex one and warrants further research into the effect of DPP-4 inhibition on the immune system to understand the pathogenesis more clearly. Whether a particular cluster of autoimmune diseases is associated with DPP-4i use remains an important contentious issue. Nevertheless, a heightened awareness from the clinicians is required to identify and treat any such diseases. Through this review, we explore the clinical and pathophysiological characteristics of this association in light of recent evidence.

show abstract

Sitagliptin

2019

Reactions Weekly

View full text Add to dashboard Cite

Exacerbation of well‐controlled bullous pemphigoid by the administration of a dipeptidyl peptidase‐4 inhibitor

Cited by 3 publications

References 5 publications

The role of Dipeptidyl Peptidase‐4 in cutaneous disease

The role of Dipeptidyl Peptidase‐4 in cutaneous disease

Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence

Sitagliptin

Contact Info

Product

Resources

About